Safety and tolerability of intravenous-to-oral treatment and single- dose intravenous or oral prophylaxis with trovafloxacin

American Journal of Surgery

Volumn 176, Issue 6 A, 1998, Pages 74S-79S

  Williams, Debra J ^a   Hopkins, Scott ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALATROFLOXACIN; TROVAFLOXACIN;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; CANDIDIASIS; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PHOTOTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURGICAL INFECTION; VERTIGO; VOMITING;

EID: 0032465891     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(98)00224-4     Document Type: Article

References (27)

1. Hendershot EF. Fluoroquinolones. Infect Dis Clin North Am. 1995;9:715-730.
2. Hooper DC, Wolfson JS. Adverse effects. In: Hooper DC, Wolfson JS, eds. Quinolone Antimicrobial Agents. 2nd ed. Washington, DC: American Society for Microbiology; 1993:489-512.
3. Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother. 1997;39(suppl B):1-14.
4. Neu HC, Chin N-X. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother. 1994;38:2615-2622.
5. Teng R, Harris SC, Nix DE, et al. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother. 1995;36:385-394.
6. Thomson KS, Chartrand SA, Sanders CC, Block SL. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrob Agents Chemother. 1997;41:478-480.
7. Eliopoulos GM, Klimm K, Eliopoulos CT, et al. In vitro activity of CP-99,219, a new filuoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother. 1993;37:366-370.
8. Felmingham D, Robbins MJ, Ingley K, et al. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J Antimicrob Chemother. 1997;39(suppl B):43-49.
9. Spangler SK, Jacobs MR, Applebaum PC. Activity of CP-99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother. 1994;38:2471-2476.
10. Cutler NR, Teng R, Dogolo LC, et al. Penetration of trovafloxacin into CSF in healthy subjects following intravenous administration of alatrofloxacin. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996; Washington, DC: American Society of Microbiology. Abstract A5.
11. Fischman AJ, Babich JW, Bonab AA, et al. Tissue pharmacokinetics of F-18 trovafloxacin in healthy human subjects. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1997; Washington, DC: American Society of Microbiology. Abstract A-68.
12. Vincent J, Venitz J, Teng R, et al. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. J Antimicrob Chemother. 1997;39(suppl B):75-80.
13. Data on file. Pfizer Inc, New York, NY.
14. Teng R, Dogolo LC, Willavize SA, et al. Oral bioavailability of trovafloxacin with and without food in healthy volunteers. J Antimicrob Chemother. 1997;39(suppl B):87-92.
15. Taylor A, Swan S, Marbury T, et al. The effect of varying degrees of renal impairment on the safety, toleration and pharmacokinetics of trovafloxacin. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1997; Washington, DC: American Society of Microbiology. Abstract A-66.
16. van Nispen CHM, Hoepelman AIM, Rozenberg-Arska M, Verhoef J, Purkins L, Willavize SA. Double-blind, placebo-controlled, parallel group study of oral trovafloxacin on bowel microflora in healthy male volunteers. Am J Surg. 1998;176(Suppl 6A): 27S-31S.
17. Teng R, Apseloffl G, Vincent J, et al. Effect of trovafloxacin (CP-99,219) on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996; Washington, DC: American Society of Microbiology. Abstract A2.
18. Vincent J, Teng R, Dogolo LC, et al. Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. J Antimicrob Chemother. 1997;39(suppl B):81-86.
19. LeBel M, Teng R, Dogolo LC, et al. The effect of steady-state trovafloxacin on the steady-state pharmacokinetics of caffeine in healthy subjects. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996; Washington, DC: American Society for Microbiology. Abstract A1.
20. Vincent J, Hunt T, Teng R, et al. The pharmacokinetic effects of coadministration of morphine and trovafloxacin in healthy subjects. Am J Surg. 1998;176 (Suppl 6A):32S-38S.
21. Fluoroquinolones exhibit differences in their incidence of rare adverse effects. Drugs Ther Perspect. 1996;7:10-13.
22. Mitscher LA, Devasthale P, Zavod R. Structure-activity relationship. In: Hooper DC, Wolfson JS, eds. Quinolone Antimicrobial Agents. 2nd ed. Washington, DC: American Society for Microbiology, 1993:23.
23. Ferguson J, McEwen J, Patterson BE, et al. An open, observer-blinded, placebo-controlled, randomized, parallel-group study to investigate the phototoxic potential of trovafloxacin, ciprofloxacin and lomefloxacin. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996; Washington, DC: American Society for Microbiology. Abstract A15.
24. Milsom JW, Smith DL, Corman ML, et al. Double-blind comparison of single dose alatrofloxacin and cefotetan as prophylaxis of infection following elective colorectal surgery. Am J Surg. 1998;176 (Suppl 6A): 46S-52S.
25. Roy S, Hemsell D, Gordon S, et al. Oral trovafloxacin compared with intravenous cefoxitin in the prevention of bacterial infection after elective vaginal or abdominal hysterectomy for non-malignant disease. Am J Surg. 1998;176(Suppl 6A):62S-66S.
26. Donahue PE, Smith DL, Yellin AE, et al. Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Am J Surg. 1998; 176(Suppl 6A):53S-61S.
27. Roy S, Koltun W, Chatwani A, et al. Treatment of acute gynecologic infections with trovafloxacin. Am J Surg. 1998; 176(Suppl 6A):67S-73S.